These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 10363025

  • 1. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
    Soderlind KJ, Gorodetsky B, Singh AK, Bachur NR, Miller GG, Lown JW.
    Anticancer Drug Des; 1999 Feb; 14(1):19-36. PubMed ID: 10363025
    [Abstract] [Full Text] [Related]

  • 2. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
    Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T.
    Cancer Res; 1999 Aug 15; 59(16):4042-9. PubMed ID: 10463605
    [Abstract] [Full Text] [Related]

  • 3. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 15; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 4. DNA alkylation by minor groove-binding N1-alkoxyalkyl-bis-benzimidazoles.
    Gupta R, Huang L, Wang H, Lown JW.
    Anticancer Drug Des; 1995 Sep 15; 10(6):451-61. PubMed ID: 7575987
    [Abstract] [Full Text] [Related]

  • 5. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution.
    Lansiaux A, Tanious F, Mishal Z, Dassonneville L, Kumar A, Stephens CE, Hu Q, Wilson WD, Boykin DW, Bailly C.
    Cancer Res; 2002 Dec 15; 62(24):7219-29. PubMed ID: 12499262
    [Abstract] [Full Text] [Related]

  • 6. Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding.
    Bachur NR, Johnson R, Yu F, Hickey R, Applegren N, Malkas L.
    Mol Pharmacol; 1993 Nov 15; 44(5):1064-9. PubMed ID: 8246909
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, DNA binding, sequence preference and biological evaluation of minor groove-selective N1-alkoxyalkyl-bis-benzimidazoles.
    Wang H, Gupta R, Lown JW.
    Anticancer Drug Des; 1994 Jun 15; 9(3):153-60. PubMed ID: 8031450
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles.
    Yang YH, Cheng MS, Wang QH, Nie H, Liao N, Wang J, Chen H.
    Eur J Med Chem; 2009 Apr 15; 44(4):1808-12. PubMed ID: 18762358
    [Abstract] [Full Text] [Related]

  • 9. DNA minor groove binders as potential antitumor and antimicrobial agents.
    Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, Romagnoli R.
    Med Res Rev; 2004 Jul 15; 24(4):475-528. PubMed ID: 15170593
    [Abstract] [Full Text] [Related]

  • 10. DNA minor groove targeted alkylating agents based on bisbenzimidazole carriers: synthesis, cytotoxicity and sequence-specificity of DNA alkylation.
    Smaill JB, Fan JY, Denny WA.
    Anticancer Drug Des; 1998 Dec 15; 13(8):857-80. PubMed ID: 10335264
    [Abstract] [Full Text] [Related]

  • 11. Helicase inhibition by anthracycline anticancer agents.
    Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L.
    Mol Pharmacol; 1992 Jun 15; 41(6):993-8. PubMed ID: 1614415
    [Abstract] [Full Text] [Related]

  • 12. Small-molecule based delivery systems for alkylating antineoplastic compounds.
    Bielawski K, Bielawska A.
    ChemMedChem; 2008 Apr 15; 3(4):536-42. PubMed ID: 18157855
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, Mongelli N, Romagnoli R.
    J Med Chem; 2004 May 06; 47(10):2611-23. PubMed ID: 15115402
    [Abstract] [Full Text] [Related]

  • 14. Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells.
    Alpan AS, Zencir S, Zupkó I, Coban G, Réthy B, Gunes HS, Topcu Z.
    J Enzyme Inhib Med Chem; 2009 Jun 06; 24(3):844-9. PubMed ID: 18951286
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of Hoechst 33258 analogues.
    Gupta R, Wang H, Huang L, Lown JW.
    Anticancer Drug Des; 1995 Jan 06; 10(1):25-41. PubMed ID: 7535056
    [Abstract] [Full Text] [Related]

  • 16. Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: synthesis, DNA sequence specificity and biological evaluation.
    Gupta R, Liu J, Xie G, Lown JW.
    Anticancer Drug Des; 1996 Dec 06; 11(8):581-96. PubMed ID: 9022747
    [Abstract] [Full Text] [Related]

  • 17. Sequence-selective targeting of long stretches of the DNA minor groove by a novel dimeric bis-benzimidazole.
    Joubert A, Sun XW, Johansson E, Bailly C, Mann J, Neidle S.
    Biochemistry; 2003 May 27; 42(20):5984-92. PubMed ID: 12755600
    [Abstract] [Full Text] [Related]

  • 18. Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents.
    Craigo WA, LeSueur BW, Skibo EB.
    J Med Chem; 1999 Aug 26; 42(17):3324-33. PubMed ID: 10464019
    [Abstract] [Full Text] [Related]

  • 19. Non-covalent ligand/DNA interactions: minor groove binding agents.
    Nelson SM, Ferguson LR, Denny WA.
    Mutat Res; 2007 Oct 01; 623(1-2):24-40. PubMed ID: 17507044
    [Abstract] [Full Text] [Related]

  • 20. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.
    Woynarowski JM, McHugh M, Sigmund RD, Beerman TA.
    Mol Pharmacol; 1989 Feb 01; 35(2):177-82. PubMed ID: 2465485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.